Pre-made Faralimomab benchmark antibody (Whole mAb, anti-IFNA1 therapeutic antibody, Anti-IFL/IFN/IFN-ALPHA/IFN-alphaD/IFNA13/leIF D Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-IFNA1 therapeutic antibody (Pre-made Faralimomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Faralimomab is a mouse monoclonal antibody and an immunomodulator.[1][2]
| Products Name (INN Index) | Pre-Made Faralimomab Biosimilar, Whole Mab, Anti-Ifna1 Antibody: Anti-IFL/IFN/IFN-ALPHA/IFN-alphaD/IFNA13/leIF D therapeutic antibody |
|---|---|
| INN Name | faralimomab |
| Target | IFNA1 |
| Format | Whole mAb |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – nd |
| VD LC | IgG1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Medarex (Princeton NJ USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IFNA1 |
| Package |
